https://www.pharmacompass.com/radio-compass-blog always 0.8 https://www.pharmacompass.com/radio-compass-blog/avocado-for-your-healthy-heart yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-strikes-more-than-40-drugs-approvals-in-2014 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/with-a-1-2-billion-buy-concordia-re-affirms-that-old-drugs-are-indeed-gold yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fondaparinux-an-opportunity-worth-developing yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cabazitaxel-the-market-overcrowding-begins yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/can-cimetidine-a-common-antacid-be-repurposed-for-cancer yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/serious-quality-concerns-at-manufacturing-operationsof-common-pain-and-fever-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/Sanofi-ups-and-down-downs-and-up yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/The-Apple-Resear-chKit-Watch yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/move-over-statins-sartans-tinibs-it-s-time-for-cholic-chemistry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/the-silver-lining-in-ipca-s-import-alert-blues yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dr-reddy-s-largest-api-facility-maybe-the-next-to-get-banned-from-exporting-to-the-united-states yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/usfda-observations-at-dr-reddy-s-srikakulam-api-plant yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dr-reddy-s-expansion-plans-for-api-production yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/wanted-opportunities-in-the-drug-shortage-list-apis-urgently-needed-in-us-and-canada yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/the-future-of-api-manufacturing-at-dr-reddy-s yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/are-assessments-of-foreign-regulatory-usfda-edqm-inspections-fair yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/1000-year-old-remedy-maybe-a-solution-to-a-100-trillion-pharmaceutical-problem yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/who-has-the-biggest-one-sales-of-the-top-pharma-products-by-revenue yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/the-secret-drug-pricing-formula yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/why-mylan-thinks-teva-s-shares-are-toilet-paper yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/sun-pharma-has-a-new-global-quality-head-what-lies-ahead yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/where-companies-who-fail-edqm-inspections-go-wrong yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/merck-vs-merck-a-mercky-tale yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/the-next-generic-attack-brilinta-ticagrelor-xarelto-rivaroxaban-tradjenta-linagliptin-and yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/diabetes-which-new-drug-is-the-safest-fda-issues-safety-warning-on-oral-antidiabetic-blockbusters yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-and-otsuka-s-multi-billion-dollar-plan-when-blockbusters-turn-generic-deuterium-chemistry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/serious-gmp-problems-uncovered-at-lupin-anvisa-zydus-cadila-usfda yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/will-data-integrity-concerns-on-clinical-trials-done-at-gvk-biosciences-go-beyond-europe yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/haunted-teva-s-1-2-billion-pay-for-delay-penalty-which-companies-will-get-hit-next yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-chess-strategies-adopted-in-the-united-states-to-block-generics yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/niche-european-molecules-is-there-a-business-opportunity-worth-pursuing yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharmaceutical-drugs-or-airplanes-which-manufacturing-system-is-more-reliable yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/plan-an-african-safari-to-discover-the-world-s-fastest-growing-pharmaceutical-opportunity yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/the-role-of-culture-in-gmp-compliance yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/did-a-29-year-old-show-glaxosmithkline-that-it-made-a-billion-dollar-mistake yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/antibiotic-resistant-superbugs-deadlier-than-cancer-and-closer-to-you-than-you-think yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/counterfeit-drugs-toyota-s-highest-ranking-female-employee-arrested-it-s-time-to-understand yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/a-prescription-for-mobile-pharma-apps yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/is-6-49-billion-making-doctors-change-your-prescription yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/marksans-quest-life-sciences-and-the-big-indian-pharmaceutical-dilemma yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/emcure-s-import-alert-is-there-a-way-of-knowing-who-will-be-next yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/marijuana-based-medicines-highway-to-pots-of-gold yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/litigation-free-first-generic-opportunities yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/is-wockhardt-turning-the-corner-in-its-compliance-battle yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/faster-drug-approvals-in-the-u-s-through-the-21st-century-cures-act yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/novartis-plant-shut-down-creates-urgency-to-find-alternatives-to-chinese-apis yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/a-21st-century-cure-for-generics-via-the-big-data-revolution yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/does-speedy-action-by-european-agencies-suggest-revival-of-api-production-in-the-west yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/generic-challenges-the-next-first-to-files-gdufa-dues-fy-2016-and-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-approved-first-3d-printed-drug-is-no-fad-but-a-technology-you-can-easily-develop yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/u-s-celebrity-kim-kardashian-s-social-media-posts-violate-regulations-fda-issues-warning-letter yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/making-a-fortune-out-of-decades-old-prescription-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/mylan-s-great-indian-misadventure yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/glaxo-s-terrible-august-makes-safety-a-priority yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/revealed-fdas-plans-for-future-inspections yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/merck-s-top-selling-diabetes-drug-less-effective-than-a-match-stick-size-implant yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/how-little-known-lannett-may-soon-become-a-billion-dollar-generic-company yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/a-u-s-presidential-election-outcome-that-matters-to-the-pharmaceutical-industry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/next-gen-aripiprazole-pill-that-sends-messages-from-the-patient-s-stomach yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/zhejiang-hisun-s-fda-import-alert-a-new-chapter-in-the-fight-against-data-integrity yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/expansion-overdrive-still-a-long-way-before-we-write-off-chemical-synthesis yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/a-case-for-developing-novartis-entresto-the-next-mega-blockbuster-drug yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/after-ranbaxy-related-woes-compliance-issues-drag-sun-pharma-down yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/vw-s-defeat-device-versus-gvk-s-electrocardiograms-what-indian-regulators-must-make-in-india yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/tricky-balance-why-a-change-in-us-drug-pricing-policy-will-create-a-tectonic-shift-globally yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/over-100-facilities-de-list-examining-the-global-supply-chain-through-gdufa-facility-fee-payments yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/data-integrity-concerns-uncovered-in-india-china-and-taiwan yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/2015-nobel-prize-for-medicine-realizing-the-potential-of-traditional-chinese-medicine-tcm yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/is-gilead-s-harvoni-going-to-become-the-best-selling-drug-in-the-history-of-the-pharmaceutical-industry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pfizer-novartis-and-gsk-s-chinese-and-indian-operations-in-compliance-trouble yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/what-s-next-as-the-mylan-perrigo-saga-ends-pfizer-allergan-begins yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/supply-chain-risk-16nov2015-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/supply-chain-risk-23nov2015-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dr-reddy-s-troubles-with-the-fda-and-the-color-purple yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/price-gouging-niche-drugs-a-main-focus-of-third-quarter-dmf-filings-with-the-fda yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/generic-disruption-awaits-veterinary-medicine yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/chemical-supply-chain-risks-30nov2015-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/supply-chain-risks-7dec2015-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-s-third-strike-at-the-japanese-generic-market-the-new-favorite-of-drug-makers yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-stories-of-the-year-digitally-smart-drugs-mergers-and-price-gouging yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/compiled-all-cgmp-non-compliances-of-2015 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/detected-hydrogen-cyanide-contamination-in-drug-shipments-from-explosions-in-tianjin-china yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/zydus-cadila-sun-pharmaceuticals-fda-warning-letters-find-problems-aplenty yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/supply-chain-risks-for-the-week-of-4jan2016-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/supply-chain-risks-4jan2016-part-two-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/supply-chain-risks-11jan2016-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/gsk-s-niquitin-nicotine-film-strips-effectiveness-questioned-in-whistleblower-lawsuit yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-drug-approvals-in-2015-novel-drugs-new-versions-of-existing-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/merck-vs-merck-the-battle-goes-digital yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/supply-chain-risk-25jan2016-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/an-inconvenient-truth-about-chinese-drug-manufacturing yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/paracetamol-apap-price-trend-data-based-on-indian-trade-export-statistics-for-q4-2015 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/paracetamol-apap-price-trend-data-based-on-indian-trade-import-statistics-for-q4-2015 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/supply-chain-risks-1feb2016-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/regulated-vs-less-regulated-markets-how-much-do-prices-of-active-pharmaceutical-ingredients-apis-vary-based-on-destination yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/non-compliant-drugs-from-asia-well-you-get-what-you-pay-for yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharmacompass-weekly-recap-compliance-and-safety-snags-dominate-deadlines yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/the-2015-data-integrity-cheat-sheet-5-questions-every-drug-maker-needs-to-answer yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/supply-chain-risks-for-15feb2016-by-charlotte-hicks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/no-rocket-science-audit-trails-a-guide-to-resolving-fda-s-biggest-concern yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-record-fines-for-pfizer-gsk-canada-adopts-ich-q8-q9-q10-zika-s-threat-to-rio-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-data-integrity-problems-in-china-free-academic-research-papers-novartis-s-problems-in-south-korea-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-another-heparin-scandal-in-china-gsk-may-have-a-new-ceo-female-libido-pill-problems yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-revenue-in-2015-who-sold-the-biggest-blockbuster-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-ranbaxy-whistleblower-takes-indian-govt-to-court-merck-claims-us-3-billion-from-gilead-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-sanofi-bets-big-to-end-use-of-injections-valeant-s-600-million-earnings-typo-ranbaxy-whistleblower-s-plea-dismissed-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-it-s-raining-data-integrity-problems-in-india-china-s-90-million-vaccine-scandal-j-j-s-tough-week-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-gilead-to-pay-merck-200-million-novartis-doctor-bribery-scandals-world-s-first-3d-printed-drug-launched-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-pfizer-allergan-end-megamerger-gsk-wants-to-make-copying-its-drugs-easier-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/drugs-with-no-patents-and-no-competition-here-s-our-list-of-new-price-gouging-targets yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-india-may-ban-animal-derived-gelatin-capsules-fda-warning-letter-trends-next-gen-nexium-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/clinical-fiascos-what-falsified-electrocardiograms-ecgs-mean-for-india-s-generic-drug-industry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/data-integrity-roundup-fda-s-guidance-note-problems-in-china-and-record-approvals-in-2015 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/school-children-face-chinese-chemical-plants-pollution-wrath yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-novartis-may-sell-roche-stake-perrigo-s-ceo-to-head-valeant yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/phispers-ims-health-merges-with-quintiles-fda-compliance-director-s-pay-package-j-j-s-talcum-powder-s-cancer-risk yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/ranbaxy-s-singh-brothers-to-pay-daiichi-sankyo-us-529-million-an-api-mega-merger-valeant-wannabe-endo-faces-a-meltdown-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-reveal-no-slowdown-in-india-china yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/capsugel-s-u-s-plant-has-data-integrity-issues-billion-dollar-chinese-bid-for-indian-sterile-manufacturer-pfizer-mylan-s-dermatology-bet yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-recent-inspection-focus-a-gmp-intelligence-overview-with-barbara-unger yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/monsanto-rejects-bayer-s-us-62-billion-bid-gmp-problems-in-germany-india-china-fda-puts-out-new-policy yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/gmp-problems-at-teva-s-hungary-plant-place-it-on-fda-s-import-alert-list-alibaba-halts-online-sale-of-medicines yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/sandoz-mylan-hetero-lupin-face-the-heat-due-to-data-manipulation-at-semler yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-s-fresh-troubles-over-drug-safety-bollygarchs-drug-price-gouging-in-britain-sun-pharma-downsizes-u-s-operations yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/lupin-s-fda-inspections-how-serious-are-the-concerns yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dr-reddy-s-faces-penalties-in-the-us-metformin-found-in-american-waters-interpol-seizes-illicit-medicines yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/microsoft-linkedin-s-disruption-potential-in-the-world-of-pharma yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/india-cracks-the-whip-on-quality-and-compliance-eli-lilly-loses-patent-infringement-case-in-china yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/what-does-brexit-mean-for-the-global-pharma-industry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-and-eu-compete-on-regulatory-vigor-former-chiefs-seek-elevation-of-status-for-fda yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/18-reasons-spelt-out-by-peter-j-werth-to-delete-analytical-data yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/data-integrity-has-no-relationship-with-product-quality yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-chief-named-in-payments-controversy-fake-vaccine-scandal-impacts-indonesian-children yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/m-a-activity-in-pharma-picks-up-cadila-lupin-alembic-close-issues-with-fda yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/this-year-internal-audit-verification-is-a-hotter-topic-for-fda-than-data-integrity yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/gsk-uses-apple-s-researchkit-for-clinical-research-india-s-pharma-exports-drop-in-q1 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/did-abbott-s-sales-rep-kill-himself-due-to-work-pressure-clinton-s-vp-nominee-under-scrutiny-for-receiving-favors-from-teva-s-barr yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-facilities-were-issued-the-most-warning-letters-by-fda-this-year yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/i-was-referring-to-data-integrity-issues-of-api-only-manufacturers yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/if-deleting-electronic-records-is-okay-then-it-must-be-okay-to-rip-out-pages-from-lab-notebooks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/gsk-google-form-first-bioelectronics-firm-11-generic-companies-benefit-from-the-teva-allergan-deal yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/compliance-troubles-emerge-at-pfizer-teva-wockhardt-and-xiamen-origin yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/china-proposes-new-drug-registration-rules-india-eases-norms-for-clinical-trials yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/ranbaxy-s-path-of-deception-revealed-in-singapore-court-order-chinese-indian-american-and-spanish-firms-in-compliance-troubles yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/sanofi-s-rough-week-quality-snags-at-pfizer-fda-warns-against-commonly-used-drug yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-issues-warning-letter-to-recently-sold-sun-pharma-facility-over-drug-contamination-concerns yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/divis-pharma-refuses-fda-inspection-lands-up-on-the-import-alert-list yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/mylan-s-epipen-price-hike-defense-india-throws-out-plans-of-a-bulk-drug-policy yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/india-steps-up-efforts-to-improve-drug-quality-allergan-vows-to-limit-price-hikes yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/india-china-absent-as-countries-align-on-global-pharma-quality-standards yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-haunted-by-problems-at-chinese-plant-sun-pharma-gets-entangled-in-price-gouging-furor yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/gsk-gets-new-ceo-clinical-researchers-to-become-more-accountable yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/assuring-integrity-in-quality-systems-a-european-manufacturer-s-perspective yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pfizer-won-t-split-mylan-ceo-draws-flak-for-flying-private-jet yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-s-ranbaxy-like-mess-builds-up-in-mexico yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/with-frauds-trust-was-broken-between-regulators-and-drug-firms yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/price-gouging-by-aspen-in-italy-explosion-at-basf-india-acts-on-illegal-metformin-exports yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/improving-compliance-and-profitability-by-opening-deviations yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/data-integrity-concerns-in-europe-at-teva-interpharma-raise-the-drug-shortage-versus-quality-debate yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-uncovers-systemic-data-manipulation-in-china-india-s-pharma-lobby-rubbishes-report-on-pollution yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-probe-crashes-indian-pharma-stocks-sanofi-novartis-gsk-do-not-effectively-disclose-clinical-trial-data yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-industry-under-trump-administration-don-t-uncork-the-bubbly-just-yet yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/china-shuts-plants-of-major-antibiotic-producers-to-fight-pollution-more-troubles-for-teva yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/compliance-wrap-heparin-quality-concerns-re-emerge-in-china-more-trouble-at-sun-pharma-wockhardt yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-to-market-cannabis-inhaler-fda-makes-quality-metrics-voluntary yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/record-fine-levied-on-pfizer-for-hiking-drug-price-us-senate-clears-biggest-drug-approval-reform yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-dmf-filings-indicate-a-robust-api-industry-with-multiple-first-to-file-challenges yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/venture-capitalist-likely-to-head-usfda-layoffs-at-sanofi-lilly-mylan-astrazeneca-and-endo yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/how-to-find-the-right-partner-company-as-gdufa-ii-proposes-a-drastic-fee-structure-change yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/emcure-s-us-ceo-looted-millions-fixed-prices-with-mylan-teva-and-others yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/346-eu-medicines-under-review-as-data-integrity-concerns-emerge-at-another-cro-in-india yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/drug-costs-and-prescription-trends-in-the-united-states-analyzing-medicare-s-121-billion-spend yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/trump-s-comments-on-drug-prices-sink-pharma-stocks-teva-lowers-guidance-by-1-billion yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/2016-a-year-of-data-integrity-issues-and-pharma-non-compliances yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-uncovers-document-shredding-through-cctv-review-data-integrity-concerns-in-india-japan-china yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/compliance-will-get-you-more-business yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-industry-unveils-new-campaign-to-repair-reputation-did-takeda-pay-a-heavy-price-for-its-5-2-billion-buy-of-ariad yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/what-does-this-mean-donald-trump-s-oval-office-meet-with-global-pharma-ceos yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/eu-suspends-drugs-from-granules-indian-facility-where-fda-had-no-concerns yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-2016-approvals-of-new-drugs-formulations-strengths-more yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/will-a-spanish-drug-retailing-for-under-10-euros-get-sold-in-the-u-s-for-89-000-year yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-ceo-steps-down-fda-warning-letters-to-firms-in-japan-india-china yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-introduces-bills-to-let-fda-recall-unsafe-drugs-allow-drug-imports-from-canada yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pfizer-s-us-facility-receives-a-warning-letter-as-baxter-s-cgmp-deficiencies-result-in-multi-million-dollar-legal-settlement yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-15-pharmaceutical-companies-by-drug-sales-in-2016 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/seven-of-your-facilities-are-out-of-compliance-fda-tells-wockhardt-mylan-s-epipen-sales-crash yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-and-eu-differ-on-cgmp-standards-at-the-same-facilities-how-will-they-mutually-recognize-inspections yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/trump-nominates-new-fda-head-import-alert-lifted-for-sun-s-mohali-facility yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/divi-s-labs-on-fda-s-import-alert-list-but-did-it-refuse-an-inspection yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/singh-bros-hit-back-at-daiichi-in-ranbaxy-case-new-drug-shortages-legislation-in-canada yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/divi-s-inspection-reveals-fda-s-shifting-focus-beyond-audit-trails yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/trumpcare-receives-a-blow-ema-to-suspend-300-drugs-due-to-clinical-data-integrity-violations-in-india yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-enforcement-actions-are-putting-the-global-pharmaceutical-supply-chain-at-risk yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/could-the-ranbaxy-whistleblower-head-the-fda-office-in-india-reprieve-for-gsk-as-mylan-s-advair-generic-gets-delayed yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/ghosts-of-gsk-s-billion-dollar-mistake-return-new-date-for-electronic-submissions-of-dmfs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-cites-data-integrity-concerns-at-mylan-product-quality-issues-at-indoco yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-in-2016-who-sold-the-blockbuster-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/more-bad-news-engulfs-teva-india-to-bring-laws-so-that-doctors-prescribe-generics yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/sanofi-lawsuit-highlights-mylan-s-unfair-trade-practices-fresenius-goes-on-multi-billion-dollar-spending-spree yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/warning-letters-reveal-issues-at-divi-s-india-teva-china-and-lonza-usa yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/ich-q11-the-regulation-that-will-transform-the-global-pharma-supply-chain yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/big-changes-at-teva-fda-approves-one-of-the-world-s-costliest-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/does-the-fda-promote-european-manufacturers-over-others-the-ice-bucket-challenge-winner yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/lesser-known-indian-firms-show-blatant-disregard-for-compliance-get-fda-warning-letters yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/chemical-entities-shine-in-the-top-10-fastest-growing-drugs-of-2016 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-reorganizes-inspection-staff-thermo-fisher-buys-patheon-for-5-2-billion yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-may-get-foreign-ceo-fda-warns-drug-makers-to-check-water-systems yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharmacompass-finds-500-drugs-with-no-patents-and-no-competition-in-the-fda-orange-book yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/market-challenges-end-india-s-pharma-honeymoon yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/who-grants-all-clear-to-mylan-s-india-facility-where-fda-had-data-integrity-concerns yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/after-beef-india-may-ban-gelatin-capsules-gsk-gilead-s-hiv-race-heats-up yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/j-j-s-diabetes-drug-reduces-heart-risk-at-the-cost-of-toes-google-s-ai-eye-doctor-initiative yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/india-leads-dmf-submissions-to-the-fda-during-q4-of-2016-and-q1-of-2017 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/investors-up-ante-against-mylan-board-more-ipca-products-banned-from-the-us yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-problems-at-pfizer-s-us-facility-continue-china-fda-joins-ich yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/mylan-board-survives-shareholder-meet-evaluate-lowers-drug-sales-growth-forecast yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-proposes-delayed-track-and-trace-rollout-gsk-forays-into-artificial-intelligence-aided-drug-research yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/biocon-s-biosimilars-program-fails-european-cgmp-inspection yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-sues-ex-exec-romantically-involved-with-apotex-s-ceo-pfizer-bids-adieu-to-brazil-s-teuto yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/can-biocon-mylan-combine-overcome-its-biosimilar-program-s-european-inspection-failure yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/trump-tells-fda-to-fund-itself-fully-through-industry-fees-astra-s-ceo-dumps-teva-offer yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/gsk-s-overhaul-begins-under-new-ceo-sandoz-loses-us-940-million-lawsuit yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/india-china-border-tension-may-impact-billion-dollar-pharma-deal-az-s-investors-worry-as-key-cancer-drug-fails-trial yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/mid-2017-recap-of-fda-warning-letters-import-alerts-eu-non-compliances yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-to-sell-assets-to-reduce-debt-lay-off-7-000-workers-shkreli-awaits-sentence yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dr-reddy-s-fails-eu-inspection-trump-disbands-business-councils-after-merck-ceo-and-others-quit-it-over-intolerance yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-to-share-full-inspection-reports-with-eu-difficult-week-for-teva-j-j-mylan yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/hetero-labs-receives-fda-warning-letter-data-integrity-concerns-at-bristol-labs-in-uk yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-announces-generic-drug-user-fees-for-fy18-gilead-acquires-kite-for-us-12-billion yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-deals-investments-and-m-as-in-august-2017 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-to-strengthen-drug-manufacturing-inspections-a-person-of-indian-origin-to-head-novartis yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/lundbeck-s-ceo-to-head-teva-pfizer-gets-fda-warning-letter-for-supplying-faulty-epipens yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pfizer-sues-j-j-generics-under-pressure-china-s-fosun-resurrects-deal-to-buyout-india-s-gland yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/re-inspection-of-divi-s-vizag-unit-indicates-a-long-haul-ahead yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/axovant-s-hyped-alzheimer-s-drug-fails-trial-as-pfizer-emulates-axovant-amneal-and-impax-in-merger-talks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/biocon-now-in-data-integrity-net-chinese-money-on-lookout-for-generic-firms yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dead-fish-in-hyderabad-puts-pharma-majors-under-scrutiny-false-data-uncovered-in-astrazeneca-us-4-billion-buy yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/data-integrity-concerns-at-baxter-s-us-625-million-buy-in-india-did-pharma-bribes-fund-terrorism-in-iraq yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-deals-investments-and-m-as-in-september-2017 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-ema-mutual-inspection-recognition-goes-live-data-integrity-issues-at-two-firms-in-india yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/mylan-s-president-emcure-s-ceo-named-in-us-drug-price-fixing-probe-novartis-buys-french-biotech-for-us-3-9-billion yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-s-rating-cut-to-junk-two-lupin-facilities-receive-fda-warning-letters yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/one-in-six-facilities-fail-to-pay-fda-s-user-fees-is-the-us-generic-supply-chain-at-risk yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pfizer-exits-china-venture-with-hisun-fda-mulls-more-steps-to-increase-generic-drug-competition yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/amsterdam-to-host-ema-china-pulls-skype-out-of-app-stores yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-s-new-ceo-pulls-out-the-axe-to-put-focus-back-on-generics-new-ema-guidance-to-help-companies-prepare-for-brexit yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-deals-investments-and-m-as-in-october-2017 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/teva-plans-10-000-job-cuts-former-ceo-cites-reasons-for-the-downfall-data-integrity-concerns-emerge-in-india-and-bangladesh yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-deals-investments-and-m-as-in-november-2017 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/2017-recap-of-warning-letters-import-alerts-and-non-compliances yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dr-reddy-s-gmp-problems-provide-a-guide-for-upcoming-fda-inspections yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/sales-forecast-of-fda-s-new-drug-approvals-of-2017 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/india-s-antibiotic-crisis-pollution-unapproved-drugs-overdosed-poultry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/china-de-risking-new-regulations-the-pharma-outsourcing-challenges-of-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-deals-investments-and-m-as-in-january-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/compliance-recap-data-integrity-threatens-us-4-3-billion-fresenius-akorn-deal yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-deals-investments-and-m-as-in-february-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/mhra-publishes-data-integrity-guidance-document-fda-posts-483s-of-major-indian-firms yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-in-2017-who-sold-the-blockbuster-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/apc-the-applied-process-company-expands-its-executive-team-with-the-appointment-of-david-downey-as-chief-commercial-officer-and-eoin-mcmanus-as-chief-operating-officer yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/api-industry-is-facing-serious-headwinds-that-require-re-strategizing-business-models yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/there-is-no-quality-control-unit-emerging-fda-concerns-in-india yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-france-uk-launch-strikes-on-syria-after-chemical-attack yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/a-case-for-developing-novartis-entresto-the-next-mega-blockbuster-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-deals-investments-and-m-as-in-march-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/compliance-recap-data-integrity-concerns-re-emerge-out-of-india-china yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-biotech-and-pharma-deals-in-april-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/compliance-recap-cgmp-non-compliance-concerns-continue-to-arise-out-of-asia yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharma-biotech-deals-investments-and-m-as-in-may-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/analyzing-over-us-90-billion-of-medicare-prescription-drug-part-d-spending-in-2016 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-pharma-biotech-deals-investments-m-as-june-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/mid-2018-recap-of-warning-letters-import-alerts-and-non-compliances yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/kemiex-reduces-the-risk-of-payment-redirection-frauds-for-pharma-industry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-pharma-biotech-deals-investments-m-as-july-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-pharma-biotech-deals-investments-m-as-in-august-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-bans-import-of-all-apis-from-zhejiang-huahai-eu-issues-non-compliance-certificate yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-pharma-biotech-deals-investments-m-as-in-september-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/mylan-s-troubles-run-deep-us-plant-receives-warning-letter-eu-suspends-valsartan-certificate-of-suitability yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/as-us-generic-businesses-face-headwinds-more-facilities-fail-to-pay-fda-s-user-fees yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharmaflow-in-october-deal-making-picks-up-pharma-companies-invest-in-capacity-building yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/valsartan-may-have-been-contaminated-since-2011-says-fda-warning-letter-to-huahai yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pharmaflow-in-november-biopharma-stock-slump-continues-as-dealmaking-picks-up yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/sales-forecast-of-fda-s-novel-drugs-approvals-in-2018 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/2018-was-a-landmark-year-for-pharma-biotech-sector-2019-looks-even-better yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/2018-compliance-recap-deficient-inspections-fragile-global-supply-chain-and-uncertain-product-quality yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/recurring-cgmp-problems-at-lupin-dr-reddy-s-data-integrity-concerns-at-indoco-vipor yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-market-offers-niche-opportunities-reveals-manufacturer-sales-data-from-medicare-part-d yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/usfda-china-share-list-of-drugs-that-need-generic-alternatives yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/compliance-to-determine-the-success-of-mylan-s-merger-with-pfizer-s-upjohn yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cmos-and-generic-suppliers-have-same-objective-but-reach-their-goals-differently yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-highlights-data-manipulation-concerns-with-novartis-gene-therapy-drug yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/aurobindo-s-contract-manufacturer-and-emcure-receive-fda-warning-letters yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-warning-letter-to-turkish-firm-over-possible-penicillin-contamination-of-cancer-drug yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/data-integrity-concerns-at-aurobindo-fda-issues-warning-letters-to-glenmark-torrent yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-issues-form-483-to-cipla-warning-letters-to-torrent-glenmark-posted yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cannabinoids-in-pharmaceutical-development yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/novartis-leads-in-new-drug-approvals-vertex-s-cystic-fibrosis-med-holds-highest-sales-potential yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-generic-drug-supply-chain-continues-to-shrink yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-in-2019-india-maintains-bulk-drug-supply-supremacy-to-us yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/mysterious-coronavirus-outbreak-may-disrupt-global-drug-supply-chains yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/world-looks-for-effective-treatment-to-coronavirus-as-drugmakers-regulators-race-ahead-to-find-vaccines-cure yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cgmp-non-compliance-recap-2019 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/covid-19-india-restricts-drug-exports-amid-rising-prices-of-essential-bulk-drugs-fda-announces-first-drug-shortage yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/hydroxychloroquine-hype-versus-reality yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/chinese-industrial-activity-revival-at-98-6-percent-officials-assure-of-api-supplies yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/covid-19-hcq-update-studies-in-france-brazil-china-raise-more-questions-on-its-efficacy-safety yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-drugs-and-pharmaceutical-companies-of-2019-by-revenues yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/new-drug-approvals-by-fda-ema-mid-2020-recap yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-gets-embroiled-in-electoral-politics-grants-eua-to-convalescent-plasma-therapy yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-in-2020-industry-sustains-its-filing-momentum yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/usfda-s-list-of-drugs-that-need-generic-alternatives yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-prescription-drugs-used-in-us-households yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-1000-pharma-companies-in-2020 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/generic-drug-manufacturing-on-rebound-fda-witnesses-uptick-in-facility-registrations yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/new-drugs-approvals-by-fda-and-ema-2020-recap yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-pharma-biotech-deals-in-2020 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cgmp-non-compliance-recap-2020 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/astrazeneca-s-covid-jab-faces-crisis-of-confidence-as-europe-halts-vaccinations-due-to-adverse-events yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-drugs-and-pharma-companies-by-sales-in-2020 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/hyaluronic-acid-latest-developments-in-a-booming-market yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/new-drug-approvals-by-fda-and-ema-mid-2021-recap yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/usfda-s-list-of-off-patent-drugs-that-need-generic-alternatives yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/china-s-energy-crunch-threatens-pharma-supply-chains yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-readies-gdufa-iii-as-us-strives-to-achieve-its-distant-dream-of-self-sufficiency-in-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/america-s-drug-price-hike-conundrum-in-backdrop-of-2019-medicare-part-d-data yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/new-drug-approvals-by-fda-ema-in-2021 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-100-pharma-biotech-deals-in-2021 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-in-2021-india-china-continue-to-top-filings yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-list-of-off-patent-drugs-highlights-continued-drop-in-generic-approvals yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/ophthalmic-dealmakers-novartis-abbvie-forge-deals-to-develop-ocular-gene-therapies yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-tracker-rising-demand-to-ensure-more-growth-consolidation-in-2022 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2021-covid-vaccines-pills-cause-churn-in-list yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/nephrology-newsmakers-fda-approves-bayer-s-kerendia-astra-s-farxiga-csl-vifor-deal-faces-regulatory-snag yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dermatology-newsmakers-sanofi-works-on-acne-vaccine-cell-and-gene-therapies-to-treat-rare-skin-diseases-gain-traction yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/biosynthesis-tech-advancements-trigger-high-growth-in-medical-cannabinoids yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-list-of-off-patent-off-exclusivity-drugs-sees-steep-rise-in-new-drug-applications yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/new-drug-approvals-by-fda-ema-health-canada-in-first-half-of-2022 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-q2-sees-more-deals-partnerships-m-as-and-expansions yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/company-tracker-novartis-robust-pipeline-new-technology-platforms-hold-promise yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-braces-for-user-fee-reauthorization-delay-even-as-dmf-submissions-rise-in-h1-2022 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/neurology-newsmakers-big-pharma-forges-deals-to-find-cures-for-cns-disorders yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/deaths-of-gambian-children-is-a-wake-up-call-for-drug-regulators-across-the-world yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-q3-sees-increased-dealmaking-expansion-in-cdmo-space yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/company-tracker-promising-pipeline-to-push-up-abbvie-revenues-despite-erosion-in-humira-sales yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/respiratory-newsmakers-rsv-vaccines-novel-targeted-therapies-gain-prominence yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-list-of-off-patent-drugs-suggests-higher-approvals-of-first-generics-in-2022 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-483-alert-intas-employees-tore-documents-threw-acid-to-destroy-evidence yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-drug-approvals-drop-26-due-to-covid-okays-three-costly-gene-therapies-in-h2 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-rise-12-1-in-2022-india-sees-10-6-drop-in-type-ii-filings yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/amgen-ends-humira-s-20-year-reign-in-us-with-amjevita-launch yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/after-cough-syrup-deaths-contaminated-eye-drops-haunt-indian-drug-industry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-100-pharma-biotech-deals-in-2022 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/endocrinology-newsmakers-drugmakers-work-on-triple-agonist-treatments-oral-insulin-to-fight-diabetes yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/company-tracker-pfizer-turns-to-acquisitions-as-covid-products-sales-nosedive yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmos-expand-operations-in-cell-and-gene-therapies-biologics-hpapis yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/drop-in-covid-sales-trial-failures-restructuring-trigger-steep-rise-in-layoffs-in-q1-2023 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-and-drugs-in-2022-pfizer-breaks-us-100-billion-barrier-abbvie-s-humira-retains-second-spot yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/drug-shortages-reach-record-high-amidst-changing-regulatory-environment yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/glp-1-ras-gain-popularity-as-cure-for-obesity-get-explored-for-nash-cvds yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-q2-sees-expansion-of-operations-continued-focus-on-c-g-therapies-hpapis yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/immunology-newsmakers-merck-acquires-prometheus-for-us-10-8-bn-first-cell-therapy-for-type-1-diabetes-bags-fda-nod yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-touch-five-year-high-in-h1-2023-china-springs-back-with-46-5-rise-in-filings yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-june-2023-list-of-off-patent-off-exclusivity-drugs-sees-steep-rise-in-new-drug-applications yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-reports-62-5-growth-in-new-drug-approvals-in-h1-2023-ema-health-canada-see-drop yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/m-a-deals-surge-in-h1-2023-as-pfizer-merck-sanofi-lilly-announce-buyouts yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-biologics-spur-growth-in-lipid-based-agents-asahi-kasei-opens-new-plant yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-taps-patheon-to-augment-wegovy-supply-wuxi-sets-up-standalone-vaccine-plant yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/india-continues-to-top-fda-registered-generics-facilities-sets-up-20-new-units-for-fy24 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/drug-shortages-persist-in-us-europe-astra-s-rsv-therapy-faces-overwhelming-demand yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/job-cuts-double-in-2023-pfizer-bms-novartis-biogen-downsize-to-cut-costs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/pfizer-s-buyout-of-seagen-drugmakers-suing-us-govt-obesity-drugs-make-it-to-top-10-phispers-of-2023 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-approvals-rise-49-in-2023-crispr-s-gene-editing-therapy-sees-light-of-day yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-steps-in-to-address-challenges-faced-by-cell-and-gene-therapies yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-approves-four-oligonucleotide-therapies-in-2023-novartis-gsk-novo-bet-big yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2023-merck-s-keytruda-emerges-as-top-selling-drug-novo-lilly-sales-skyrocket-due-to-glp-1-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-from-china-jump-42-as-india-continues-to-top-list-in-q1-2024 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/big-pharma-bets-big-on-ai-s-us-148-bn-potential-to-revolutionize-healthcare-industry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-approves-record-eight-biosimilars-in-h1-2024-okays-first-interchangeable-biosimilars-for-eylea yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-june-2024-list-of-off-patent-off-exclusivity-drugs-sees-rise-in-cancer-hiv-treatments yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-approvals-slump-19-in-h1-2024-nash-copd-pah-get-new-treatment-options yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/novartis-gsk-sanofi-bms-shell-out-over-us-10-bn-in-dealmaking-as-mid-size-deals-take-centerstage-in-2024 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-hit-record-high-in-q1-2024-impacts-cancer-adhd-drugs-lilly-novo-ramp-up-production yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/bms-bayer-takeda-pfizer-downsize-to-combat-cost-pressures-meet-restructuring-plans yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-europe-turn-to-advanced-manufacturing-stockpiling-to-strengthen-drug-supply-chains yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-landmark-approvals-of-bms-schizo-med-madrigal-s-mash-drug-us-16-5-bn-catalent-buyout-make-it-to-top-10-news-of-2024 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-first-generic-approvals-slump-21-in-2024-novartis-top-seller-entresto-cancer-blockbuster-tasigna-lead-2024-patent-cliff yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-first-in-class-drug-candidates-of-2025-ionis-donidalorsen-sanofi-s-fitusiran-cytokinetics-aficamten-await-fda-approval yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/ai-drug-discovery-market-to-grow-30-cagr-to-reach-us-35-bn-by-2034-novo-lilly-bms-forge-deals yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-axplora-enhances-adc-capacities-quotient-beefs-up-hpapi-capabilities-evonik-euroapi-forge-deals yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/how-trump-s-tariffs-on-imported-drugs-can-hurt-supply-chains-consumers-and-industry yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-evonik-launches-high-purity-excipients-india-mandates-disclosures-from-march-2026 yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/antibiotic-market-to-reach-us-74-07-billion-by-2033-fda-approves-gsk-s-blujepa-for-uncomplicated-utis yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-lupin-s-cdmo-commissions-oncology-block-in-india-cambrex-axplora-hovione-expand-operations yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/top-news-of-2025-drugmakers-invest-in-us-capacities-agree-to-lower-medicaid-prices-pfizer-buys-obesity-focused-biotech-metsera yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-s-december-2025-opoe-list-features-784-prescription-drugs-73-otc-drugs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-8-in-2025-with-fewer-blockbusters-brinsupri-rhapsido-make-it-to-first-in-class-list yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-clariant-sets-up-its-first-peg-excipients-facility-in-us-india-harmonizes-22-excipient-monographs yearly 0.6 https://www.pharmacompass.com/radio-compass-blog/cep-q1-2026-update-cep-2-0-edqm-s-new-guidelines-strengthen-ecosystem-indian-firms-top-list-of-ceps-issued yearly 0.6